KLRB1 Antibody

說明書

中文名稱：

KLRB1兔多克隆抗體
貨號：

CSB-PA005290
規格：

￥1090
圖片：
Western Blot analysis of K562 cells using CD161 Polyclonal Antibody
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

Q12918
基因名：

KLRB1
別名：

C-type lectin domain family 5 member B antibody; CD161 antibody; CLEC5B antibody; HNKR-P1a antibody; Killer Cell Lectin like Receptor Subfamily B Member 1 antibody; Killer cell lectin-like receptor subfamily B member 1 antibody; KLRB1 antibody; KLRB1_HUMAN antibody; Natural killer cell surface protein P1A antibody; NKR antibody; NKR P1 antibody; NKR-P1A antibody; NKRP1 antibody; NKRP1A antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Synthesized peptide derived from the Internal region of Human CD161.
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

WB, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
ELISA	1:20000

Protocols：

Western Blotting (WB) Protocol
ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.
基因功能參考文獻：
1. These results show that susceptibility of normal articular chondrocytes to lysis by NK cells is modulated by NKR-P1A/LLT1 interactions. Thus, NKR-P1A/LLT1 interaction might provide some novel target for therapeutic interventions in the course of pathological cartilage injury. PMID: 29212911
2. Blocking LLT1-NKRP1A interaction will make prostate cancer cells susceptible to killing by NK cells, suggesting a therapeutic option for treatment of prostate cancer. PMID: 27626681
3. Purified soluble NKR-P1 is homogeneous, deglycosylatable, crystallizable and monomeric in solution, as shown by size-exclusion chromatography, multi-angle light scattering and analytical ultracentrifugation. PMID: 28757467
4. A subset of virus-specific CD161(+) T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in acute myeloid leukemia. PMID: 27821506
5. CD161 expression levels were reduced in some NK and T cell subpopulations of systemic lupus erythematosus (SLE) patients, suggesting possible important role of CD161 and CD161-expressing immune cells in the SLE pathogenesis. PMID: 26590595
6. A novel population of highly functional, memory CD8+ T cells enriched within the gut expresses CD161. PMID: 26220166
7. Our results reveal that in combination with IGRAs, CD161-based indices provide a novel, fast diagnostic solution addressing the limitation of current tuberculosis diagnostics. PMID: 26643453
8. these data suggest that LLT1-CD161 interactions play a novel and important role in B cell maturation within the Germinal center in humans. PMID: 26829983
9. The regulation of NK cell homeostasis and activation apparently differs between carriers of the CC and TT variant of CD161. PMID: 26309225
10. We suggest modulation of human Th17 responsiveness by CD39 and CD161 and describe novel molecular mechanisms integrating elements of both extracellular nucleotide and sphingolipid homeostasis--{REVIEW} PMID: 26059452
11. percentage of alveolar CD3(+)CD161(+) T lymphocytes that produced IFN-gamma/IL-17 was significantly higher than those in the peripheral blood PMID: 25906076
12. these results suggest that the CD8(+) subset of CD161(+) T cells may have regulatory effects and that they provide a basis for predicting the occurrence of aGVHD after allogeneic SCT. PMID: 25543092
13. CD161-expressing Th17 cells are enriched at sites of autoinflammation, are highly proinflammatory and resistant to Treg-mediated suppression suggesting their important pathogenic role in rheumatoid arthritis. PMID: 26062995
14. Expression of CD161 hence identifies a transcriptional and functional phenotype, shared across human T lymphocytes. PMID: 25437561
15. Elevated expression of CD69 and CD161 on NK cells can be considered as immunological risk markers in RSA and IVF failure. PMID: 24975965
16. CD39 and CD161 modulate human Th17 responses in CD through alterations in purinergic nucleotide-mediated responses and ASM catalytic bioactivity, respectively. PMID: 25172498
17. CD161+ Th17/CD161+ Th1-cell imbalance may contribute to the development of rheumatoid arthritis. PMID: 24392804
18. Here we present a distinct population of Treg, defined by CD161 expression, as the major source of FoxP3+ Treg-derived proinflammatory cytokines. PMID: 23355538
19. The fraction of CD161high T cells is significantly higher in cerebrospinal fluid of patients with multiple sclerosis in relapse than those of controls. PMID: 23599932
20. CD161+CD4+ T lymphocytes, differentiated into Th1 cells and Th17 cells, are involved in the pathogenesis of giant cell arteritis and polymyalgia rheumatica. PMID: 22833233
21. LLT1 and CD161 have roles in modulating immune responses to pathogens; and interferon-gamma contributes to modulate immune responses PMID: 21930700
22. our results indicate that KLRB1 gene expression is altered in multiple sclerosis (MS) and likely to be involved in the pathogenesis of the disease, whereas rs4763655 in KLRB1 seems to have a minimal role in MS susceptibility. PMID: 21610746
23. expression defines IL-25- and IL-33-responsive type 2 innate lymphoid cells PMID: 21909091
24. Molecular basis for LLT1 protein recognition by human CD161 protein (NKRP1A/KLRB1). PMID: 21572041
25. Th17 cells from patients with head and neck squamous cell carcinoma downregulate the Th17 cell surface receptor CD161 in peripheral blood as well as in primary tumors and especially in metastatic lymph nodes. PMID: 21570678
26. cytokines induce significant up-regulation of NKG2D expression while only IFN-alpha induced significant up-regulation of CD161 PMID: 20800424
27. marker of IL-17-producing T-cell subsets PMID: 20486123
28. Results reveal a functional relationship between CD161 expression and NK cell cytotoxicity as well as NK cell reactivity to glycans and mutated citrullinated vimentin, providing new insight into the pathogenesis of rheumatoid arthritis. PMID: 20359956
29. CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. PMID: 20133607
30. There is a significant positive correlation of CD161 expression with NK cytotoxicity. PMID: 19711124
31. Pl(A2) genotype is associated with a decreased risk of developing intermittent claudication. PMID: 14987913
32. Engagement of CD161 on NK cells with LLT1 expressed on target cells inhibited NK cell-mediated cytotoxicity and IFN-gamma secretion. LLT1/CD161 interaction in the presence of a TCR signal enhanced IFN-gamma production by T cells PMID: 16339512
33. LLT1 on target cells can inhibit NK cytotoxicity via interactions with CD161. LLT1 activates NFAT-GFP reporter cells expressing a CD3zeta-CD161 chimeric receptor; reciprocally, reporter cells with a CD3zeta-LLT1 chimeric receptor are stimulated by CD161 PMID: 16339513
34. define a novel signal transduction pathway for the CD161 (NKR-P1A) receptor and provide fresh insights into NK and NKT cell biology PMID: 16455998
35. NKRPIA binds to the alphaGal epitope of mouse laminin. Moreover, exposing NAcLac by removal of alphaGal resulted in an increase in binding. PMID: 16925668
36. The results of this work demonstrated that the transcription of the KLRB1 was suppressed in tumor tissues in 68% patients with nonsmall-lung-cancer (p < 0.0001) and 57% patients with esophageal squamous-cell carcinoma (p = 0.0003). PMID: 18159636
37. Expression of CD161 indicates a unique pattern of T cell differentiation that might help elucidate the mechanisms of hepatitis c virus immunity and pathogenesis. PMID: 18219672
38. Interactions between NKR-P1A on NK cells and LLT1 on target cells inhibit NK cell-mediated cytotoxicity and cytokine production PMID: 18453569
39. PILAR signaling through CD161 supports CD3 antibody-dependent and antigen-specific T-cell proliferation by increasing the expression of antiapoptotic Bcl-xL and induces secretion of T helper type 1 cytokines PMID: 18550855
40. all IL-17-producing cells originate from CD161(+) naive CD4(+) T cells of umbilical cord blood, as well as of the postnatal thymus PMID: 18663128
41. These data identify CD161(+) CD4 T cells as a resting Th17 pool that can be activated by IL-23 and mediate destructive tissue inflammation. PMID: 19273624
顯示更多

收起更多
亞細胞定位：

Membrane; Single-pass type II membrane protein.
組織特異性：

Expressed in a subset of NK cells predominantly in intestinal epithelium and liver. Detected in peripheral blood T-cells and preferentially in adult T-cells with a memory antigenic phenotype.
數據庫鏈接：

HGNC: 6373

OMIM: 602890

KEGG: hsa:3820

STRING: 9606.ENSP00000229402

UniGene: Hs.169824

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human